Gadolinium-DPTA: a radiographic contrast agent

Janon, Edward A.

doi:10.2214/ajr.152.6.1348-a

Cited by 15 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first reported use of a gadolinium-chelate as an X-ray contrast agent in humans occurred serendipitously in 1989 [7]: an "unenhanced" CT scan in a patient who had received gadopentetate (Magnevist) for MR imaging revealed unexpected X-ray contrast enhancement in the urinary tract. Since then, several reports have shown that arterial opacification on sectional computed tomography occurs after peripheral intravenous bolus injection of gadolinium-containing contrast agents in animal models as well as in patients.…”

Section: Gadolinium-chelates and Ct In Clinical Practicementioning

confidence: 99%

Actual clinical use of gadolinium-chelates for non-MRI applications

Strunk

Schild

2004

European Radiology

View full text Add to dashboard Cite

For many years, alternatives to iodinated X-ray contrast media have been sought. Of the contrast media investigated to date, only CO(2) and the gadolinium-chelates have been shown to be viable alternatives for selected X-ray examinations. Therefore, we have reviewed the general literature and that specific for gadopentetate (Magnevist) in particular, since this agent has been studied the most. This review indicates that diagnostic CT examinations can be achieved following the intravenous administration of gadolinium-containing contrast media (CM) for evaluation of aortic abnormalities. Gadolinium-containing CM at the dose approved for MR imaging are not useful for CT evaluation of the abdominal parenchymal organs. Intravenous/intraarterial injections have also been used in a variety of angiographic and interventional procedures. Image quality, however, is generally inferior to iodinated contrast media. Gadolinium-containing CM require no special handling and can be administered by hand injection or via conventional angiographic automated injectors with the same flow rates and pressures as are used with iodinated contrast media. For CT, a peripheral bolus injection of a diluted gadolinium agent (1:1 with saline) of 60-90 ml at 3-5 ml/s is usually performed. Similar to all other gadolinium-chelates, the non-MRI use of gadopentetate (Magnevist) is not approved by regulatory agencies. However, the literature suggests that a dose of 0.3-0.4 mmol/kg b.w. has been safely administered for CT as well as for angiography and interventional procedures intravenously and intraarterially. Even at this dose, though, this results in a relatively small overall volume to be injected, which limits utility somewhat.

show abstract

Section: Gadolinium-chelates and Ct In Clinical Practicementioning

confidence: 99%

Actual clinical use of gadolinium-chelates for non-MRI applications

Strunk

Schild

2004

European Radiology

View full text Add to dashboard Cite

show abstract

“…The first reported use of gadolinium for its radio-opacity was in 1989, when a CT scan showed urinary hyperattenuation 2. Gadolinium chelate use during DSA examinations has traditionally been regarded as a suboptimal alternative to iohexol-based contrast agents due to its inferior radiodensity.…”

Section: Discussionmentioning

confidence: 99%

The use of gadolinium chelates as an alternative radiographic contrast agent for use with flat panel detector angiography

Hui

Tong

Dion

2010

J NeuroIntervent Surg

View full text Add to dashboard Cite

Gadolinium chelates can be utilized as a fluoroscopic contrast agent when iodinated contrast is contraindicated. However, the nephrotoxicity of gadolinium at radiographic doses limits its role as fluoroscopic contrast. Gadolinium chelate-enhanced digital subtraction angiography (DSA) is particularly limited by the kV of DSA, where gadolinium chelates are relatively more radiolucent. Flat panel detectors improve conspicuity of gadolinium chelates during DSA and should be employed where possible.

show abstract

“…The first use of Gd-chelates as radiographic CM in CT studies was reported in 1989 by Janon and Bloem et al[5, 6] Since then, several cases using Gd-chelates in various radiographic procedures have been published. Furuichi et al reported the use of gadopentetate dimeglumine, Gd-DTPA, in the course of percutaneous coronary intervention.…”

Section: Introductionmentioning

confidence: 99%